Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma  

作　　者：Jian-Wei Zhang Tao Qin Shao-Dong Hong Jing Zhang Wen-Feng Fang Yuan-Yuan Zhao Yun-Peng Yang Cong Xue Yan Huang Hong-Yuan Zhao Yu-Xiang Ma Zhi-Huang Hu Pei-Yu Huang Li Zhang 

机构地区：[1]Sun Yat-sen University Cancer Center [2]State Key Laboratory of Oncology in South China [3]Collaborative Innovation Center for Cancer Medicine [4]Department of Medical Oncology,Sun Yat-sen University Cancer Center [5]Department of Nasopharyngeal Carcinoma,Sun Yat-sen University Cancer Center

出　　处：《Chinese Journal of Cancer》2015年第4期177-183,共7页

基　　金：supported in part by a grant from the National High Technology Research and Development Program of China(No.2012AA02A501)

摘　　要：Introduction:An increasing number of targeted drugs have been tested for the treatment of nasopharyngeal carcinoma(NPC).However,targeted therapy-related oncogenic mutations have not been fully evaluated.This study aimed to detect targeted therapy-related oncogenic mutations in NPC and to determine which targeted therapy might be potentially effective in treating NPC.Methods:By using the SNaPshot assay,a rapid detection method,19 mutation hotspots in 6 targeted therapy-related oncogenes were examined in 70 NPC patients.The associations between oncogenic mutations and clinicopathologic factors were analyzed.Results:Among 70 patients,12(17.1%) had mutations in 5 oncogenes:7(10.0%) had v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog(KIT) mutation,2(2.8%) had epidermal growth factor receptor(EGFR) mutation,1(1.4%) had phosphatidylinositol-4,5-bisphosphate 3-kinase,catalytic subunit alpha(PIK3CA) mutation,1(1.4%) had Kirsten rat sarcoma viral oncogene homolog(KRAS) mutation,and 1(1.4%) had simultaneous EGFR and v-Raf murine sarcoma viral oncogene homolog B1(BRAF) mutations.No significant differences were observed between oncogenic mutations and clinicopathologic characteristics.Additionally,these oncogenic mutations were not associated with tumor recurrence or metastasis.Conclusions:Oncogenic mutations are present in NPC patients.The efficacy of targeted drugs on patients with the related oncogenic mutations requires further validation.Introduction： An increasing number of targeted drugs have been tested for the treatment of nasopharyngeal carcinoma （NPC）. However, targeted therapy-related oncogenic mutations have not been fully evaluated. This study aimed to detect targeted therapy-related oncogenic mutations in NPC and to determine which targeted therapy might be potentially effective in treating NPC. Methods： By using the SNaPshot assay, a rapid detection method, 19 mutation hotspots in 6 targeted therapy-related oncogenes were examined in 70 NPC patients. The associations between oncogenic mutations and clinicopathologic factors were analyzed. Results： Among 70 patients, 12 （1 7.1%） had mutations in 5 oncogenes： 7 （10.0%） had v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog （KIT） mutation, 2 （2.8%） had epidermal growth factor receptor （EGFR） mutation, 1 （1.4%） had phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha （PIK3CA） mutation, 1 （IA%） had Kirsten rat sarcoma viral oncogene homolog （KRAS） mutation, and 1（1.4%） had simultaneous EGFB and v-Raf murine sarcoma viral oncogene homolog BI （BRAF） mutations. No significant differences were observed between oncogenic mutations and clinicopathologic characteristics. Additionally, these oncogenic mutations were not associated with tumor recurrence or metastasis. Conclusions： Oncogenic mutations are present in NPC patients. The efficacy of targeted drugs on patients with the related oncogenic mutations requires further validation.

关 键 词：基因突变 靶向治疗 鼻咽癌 致癌 表皮生长因子受体 快速检测方法 原癌基因 同源基因 

分 类 号：R739.63[医药卫生—肿瘤]